Clinical Trials in Pittsburgh

Showing 4521-4540 of 16,007 trials

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

NCT06892938

Everbeat is a finger-worn ring that has a built-in electrocardiogram (ECG). In this study the investigators ensure that the ECG as read by the everbeat correctly classifies heart rhythms and detects atrial fibrillation. Investigators will also correlate the everbeat ECG waveform with a clinical-grade FDA approved electrocardiogram to ensure it may be reliably interpreted by clinicians or other algorithms.

Atrial Fibrillation (AF)Arrhythmias CardiacTachycardia+2 more

Everbeat232 participantsStarted Sep 2024

La Jolla, California, United States • Baton Rouge, Louisiana, United States • Pittsburgh, Pennsylvania, United States

COMPLETEDPhase 2162 miles

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

NCT04098068

This study will be looking at whether MK-3475 (pembrolizumab) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite Unstable) negative cancer with a mutator phenotype.

High Tumor Mutation BurdenHigh TMB (Tumor Mutation Burden)MSS (Microsatellite Stable)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12 participantsStarted Jan 2018

Baltimore, Maryland, United States • New York, New York, United States • Columbus, Ohio, United States

COMPLETED162 miles

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

NCT04035226

The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).

Multiple Myeloma

Janssen-Cilag Ltd.254 participantsStarted Aug 2019

Glendale, California, United States • Greenbrae, California, United States • Weeki Wachee, Florida, United States +72 more locations

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Find Trials by Condition in Pittsburgh

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Antibiotic Prophylaxis Before Shock Wave Lithotripsy

Strength or Power Training for Patellofemoral Pain

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

Outcome of Patients with Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Vitamin D to ENhance TraUma REcovery

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

Electrical Muscle Stimulation with 1064 Nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction.

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate

Envi™-SR Randomized Controlled Trial for Endovascular Treatment of Ischemic Stroke

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants